Accès libre

Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?

Hannah Luisa Steinberg-Vorhoff

Hannah Luisa Steinberg-Vorhoff

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Steinberg-Vorhoff, Hannah Luisa
, 
Marcel Drews

Marcel Drews

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Drews, Marcel
, 
Marcel Opitz

Marcel Opitz

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Opitz, Marcel
, 
Natalie van Landeghem

Natalie van Landeghem

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Landeghem, Natalie van
, 
Luca Salhöfer

Luca Salhöfer

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Salhöfer, Luca
, 
Mathias Holtkamp

Mathias Holtkamp

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Holtkamp, Mathias
, 
Yan Li

Yan Li

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Li, Yan
, 
Johannes Haubold

Johannes Haubold

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Haubold, Johannes
, 
Jens Siveke

Jens Siveke

  • Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital EssenEssen, Germany
  • Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZHeidelberg, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Siveke, Jens
, 
Heike Richly

Heike Richly

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University of Duisburg-EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Richly, Heike
, 
Michael Forsting

Michael Forsting

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Forsting, Michael
, 
Benedikt Michael Schaarschmidt

Benedikt Michael Schaarschmidt

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Schaarschmidt, Benedikt Michael
 et 
Sebastian Zensen

Sebastian Zensen

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital EssenEssen, Germany
Recherchez cet auteur sur
Sciendo|Google Scholar
Zensen, Sebastian
  
05 sept. 2025
Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?'s Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: Research Article
Publié en ligne: 05 sept. 2025
Pages: 383 - 390
Reçu: 03 mars 2025
Accepté: 22 mai 2025
DOI: https://doi.org/10.2478/raon-2025-0047
Mots clés
© 2025 Hannah Luisa Steinberg-Vorhoff et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Flowchart of analyzed study population with exclusion criteria. HAIC = hepatic artery infusion therapy
Flowchart of analyzed study population with exclusion criteria. HAIC = hepatic artery infusion therapy

FIGURE 2.

71-year old women with uveal melanoma and liver metastases. Axial CT image examples of volumetry of liver and spleen four days before and 44 days after first hepatic artery infusion therapy (HAIC). Liver and spleen volume increased by 39% after first HAIC.
71-year old women with uveal melanoma and liver metastases. Axial CT image examples of volumetry of liver and spleen four days before and 44 days after first hepatic artery infusion therapy (HAIC). Liver and spleen volume increased by 39% after first HAIC.

FIGURE 3.

Change in spleen volume dif ferentiated by treatment response according to RECIST 1.1. Points show outliers outside the Tukey whiskers. Asterisks indicate significant differences (p ≤ 0.05).
Change in spleen volume dif ferentiated by treatment response according to RECIST 1.1. Points show outliers outside the Tukey whiskers. Asterisks indicate significant differences (p ≤ 0.05).

FIGURE 4.

Kaplan-Meier curve shows overall survival (OS) in uveal melanoma (UM) patients with and without splenomegaly before first hepatic artery infusion therapy (HAIC).
Kaplan-Meier curve shows overall survival (OS) in uveal melanoma (UM) patients with and without splenomegaly before first hepatic artery infusion therapy (HAIC).

FIGURE 5.

Overall survival of evaluation of treatment response by RECIST 1.1 (A) and spleen volumetry with a threshold of 5% (B) of spleen volume increase of uveal melanoma patients with liver metastases treated by hepatic artery infusion therapy (HAIC). Kaplan-Meier curves show overall survival (OS) separately for patients evaluated as stable disease (SD) + partial response (PR) and (progressive disease) PD. In spleen volumetry, patients with an increase in spleen volume more than 5% were classified as increased spleen volume and with decrease or increase up to 5% as stable spleen volume.
Overall survival of evaluation of treatment response by RECIST 1.1 (A) and spleen volumetry with a threshold of 5% (B) of spleen volume increase of uveal melanoma patients with liver metastases treated by hepatic artery infusion therapy (HAIC). Kaplan-Meier curves show overall survival (OS) separately for patients evaluated as stable disease (SD) + partial response (PR) and (progressive disease) PD. In spleen volumetry, patients with an increase in spleen volume more than 5% were classified as increased spleen volume and with decrease or increase up to 5% as stable spleen volume.

FIGURE 6.

Kaplan-Meier curves for the combined RECIST 1.1 and spleen volumetry evaluation of treatment response with a threshold of 5% increase in spleen volume in uveal melanoma patients with liver metastases treated by HAIC. PD = progressive disease; PR = partial response; SD = stable disease
Kaplan-Meier curves for the combined RECIST 1.1 and spleen volumetry evaluation of treatment response with a threshold of 5% increase in spleen volume in uveal melanoma patients with liver metastases treated by HAIC. PD = progressive disease; PR = partial response; SD = stable disease

Median overall survival and accordance of treatment response evaluation by RECIST 1_1 and spleen volumetry with a threshold of 5% increase in spleen volume

Spleen volumetry
RECIST 1.1 criteria Stable (spleen volume decrease or increase up to max. 5%) Increase (spleen volume increases more than 5%) Total
SD + PR 15.8 months (n = 85) 13.8 months (n = 64) 15.1 months (n = 149)
PD 9.5 months (n = 12) 8.5 months (n = 18) 8.3 months (n = 30)
Total 15.1 months (n = 97) 11.5 months (n = 82) 13.8 months (n = 179)

Patient characteristics

All patients (n = 179) Splenomegaly (n = 25) No Splenomegaly (n = 154) p-value
Age (mean/SD) 64.8 years, 11.0 years 61.9 years, 12.5 years 65.0 years, 10.7 years 0.2
Gender (female/male) 95 (53 %) / 84 (47 %) 4 (16 %) / 21 (84 %) 91 (59 %) / 63 (41 %)
Number of HAIC per patient 5 (3–10) 5 (3–11) 5 (3–9) 0.8
Spleen
  Volume before first HAIC 205 ml (150–263 ml) 362 ml (347–407 ml) 186 ml (142–237 ml) < 0.0001
  Volume after first HAIC 213 ml (155–279 ml) 385 ml (345–430 ml) 200 ml (151–241 ml) < 0.0001
  Volume change +4.0 % (-4.0 – +12.0%) + 6.5 % (-5.8 – +11.5%) +3.6 % (-3.4 – +12.2%) 0.8
Liver
  Volume before first HAIC 1731 ml (1426–2228 ml) 2358 ml (1936–2787 ml) 1637 ml (1405–2050 ml) < 0.0001
  Volume after first HAIC 1780 ml (1447–2406 ml) 2354 (1983–2894 ml) 1741 ml (1431–2240 ml) 0.0009
  Volume change +4.0 % (-2.0 – +13.0%) -0.5 % (-9.4 – +6.9%) +5.0 % (-1.7 – +13.4%) 0.04
RECIST 1.1 liver index size change +2.8 % (-6.5 – +14.3%) +2.5 % (-3.0 – +10.2%) +3.3 % (-7.2 – +16.1%) 0.7
Overall survival 13.7 months (7.3–21.2 months) 10.7 months (5.2–19.2 months) 13.8 months (7.3–21.8 months) 0.6
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Médecine, Médecine clinique, Médecine interne, Hématologie, oncologie, Radiologie
RSS Feed de la revue